NZ603411A - Pazopanib compositions and their use in treating ocular diseases - Google Patents
Pazopanib compositions and their use in treating ocular diseasesInfo
- Publication number
- NZ603411A NZ603411A NZ603411A NZ60341111A NZ603411A NZ 603411 A NZ603411 A NZ 603411A NZ 603411 A NZ603411 A NZ 603411A NZ 60341111 A NZ60341111 A NZ 60341111A NZ 603411 A NZ603411 A NZ 603411A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pazopanib
- compositions
- ocular diseases
- treating ocular
- cyclodextrin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33171510P | 2010-05-05 | 2010-05-05 | |
| PCT/US2011/035363 WO2011140343A1 (en) | 2010-05-05 | 2011-05-05 | Pharmaceutical compositions and methods of making same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ603411A true NZ603411A (en) | 2014-10-31 |
Family
ID=44851507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603411A NZ603411A (en) | 2010-05-05 | 2011-05-05 | Pazopanib compositions and their use in treating ocular diseases |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120028918A1 (enExample) |
| EP (1) | EP2566331B1 (enExample) |
| JP (1) | JP5835717B2 (enExample) |
| KR (1) | KR20130071434A (enExample) |
| CN (1) | CN102970871A (enExample) |
| AR (1) | AR081364A1 (enExample) |
| AU (1) | AU2011247995B2 (enExample) |
| BR (1) | BR112012028291A2 (enExample) |
| CA (1) | CA2798386A1 (enExample) |
| CL (1) | CL2012003075A1 (enExample) |
| CO (1) | CO6640262A2 (enExample) |
| CR (1) | CR20120556A (enExample) |
| DO (1) | DOP2012000281A (enExample) |
| EA (1) | EA201291168A1 (enExample) |
| ES (1) | ES2519615T3 (enExample) |
| IL (1) | IL222751A0 (enExample) |
| MA (1) | MA34286B1 (enExample) |
| MX (1) | MX2012012837A (enExample) |
| NZ (1) | NZ603411A (enExample) |
| PE (1) | PE20130217A1 (enExample) |
| PH (1) | PH12012502159A1 (enExample) |
| SG (1) | SG185087A1 (enExample) |
| TW (1) | TW201206908A (enExample) |
| UY (1) | UY33367A (enExample) |
| WO (1) | WO2011140343A1 (enExample) |
| ZA (1) | ZA201208265B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
| WO2012019136A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
| AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| SI2755600T1 (sl) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Naprava za izmenjavo tekočine |
| JP2015507020A (ja) * | 2012-02-17 | 2015-03-05 | ファーマサイクリックス，インク． | ヒストンデアセチラーゼ阻害剤とパゾパニブの組み合わせおよびその使用 |
| US9629021B2 (en) * | 2012-03-08 | 2017-04-18 | Samsung Electronics Co., Ltd | Method for controlling service in radio communication system |
| AU2014236455B2 (en) * | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| AU2014241163B2 (en) | 2013-03-28 | 2018-09-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| JP6612232B2 (ja) | 2013-08-28 | 2019-11-27 | クラウン バイオサイエンス インコーポレイテッド（タイカン） | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 |
| MY182793A (en) * | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| JP7037360B2 (ja) | 2014-11-10 | 2022-03-16 | フォーサイト・ビジョン フォー・インコーポレーテッド | 拡張可能な薬物送達デバイス |
| WO2016104690A1 (ja) | 2014-12-25 | 2016-06-30 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| BR112018070383A2 (pt) | 2016-04-05 | 2019-02-05 | Forsight Vision4 Inc | dispositivos para aplicação de fármaco oculares implantáveis |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| US11174253B2 (en) | 2017-08-02 | 2021-11-16 | Alphala Co., Ltd. | Compound and pharmaceutical composition containing the same |
| SI3810089T1 (sl) * | 2018-06-07 | 2023-11-30 | Pfizer Inc. | Vodna formulacija,ki vsebuje 1-(4-((4-(dimetilamino)piperidin-1-il)karbonil)fenil)-3-(4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil)sečnino |
| CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| PL1968594T3 (pl) * | 2005-11-29 | 2011-03-31 | Glaxosmithkline Llc | Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| WO2007121483A2 (en) * | 2006-04-18 | 2007-10-25 | Ekr Therapeutics, Inc. | Pre-mixed, ready-to-use iv bolus compositions and methods of use |
| MX2010004281A (es) * | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| CA2711759A1 (en) * | 2008-01-30 | 2009-08-06 | Genentech, Inc. | Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
| CN102573477A (zh) * | 2009-07-16 | 2012-07-11 | 葛兰素惠尔康制造业私人有限公司 | 治疗方法 |
| US20120232102A1 (en) * | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| UY33164A (es) * | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
| US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
-
2011
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 CA CA2798386A patent/CA2798386A1/en not_active Abandoned
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/en active Active
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Withdrawn
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/en not_active Ceased
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
- 2011-05-05 PH PH1/2012/502159A patent/PH12012502159A1/en unknown
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UY33367A (es) | 2011-10-31 |
| HK1175947A1 (en) | 2013-07-19 |
| DOP2012000281A (es) | 2013-05-31 |
| CO6640262A2 (es) | 2013-03-22 |
| AU2011247995B2 (en) | 2014-07-31 |
| CL2012003075A1 (es) | 2013-03-08 |
| BR112012028291A2 (pt) | 2015-09-15 |
| IL222751A0 (en) | 2012-12-31 |
| AR081364A1 (es) | 2012-08-29 |
| US20110281901A1 (en) | 2011-11-17 |
| EP2566331B1 (en) | 2014-09-03 |
| PH12012502159A1 (en) | 2013-02-04 |
| AU2011247995A1 (en) | 2012-12-13 |
| PE20130217A1 (es) | 2013-03-21 |
| CN102970871A (zh) | 2013-03-13 |
| CA2798386A1 (en) | 2011-11-10 |
| EA201291168A1 (ru) | 2013-06-28 |
| CR20120556A (es) | 2013-02-20 |
| TW201206908A (en) | 2012-02-16 |
| KR20130071434A (ko) | 2013-06-28 |
| JP2013525501A (ja) | 2013-06-20 |
| EP2566331A4 (en) | 2013-09-18 |
| SG185087A1 (en) | 2012-12-28 |
| MX2012012837A (es) | 2013-01-24 |
| ZA201208265B (en) | 2013-07-31 |
| ES2519615T3 (es) | 2014-11-07 |
| EP2566331A1 (en) | 2013-03-13 |
| US20120028918A1 (en) | 2012-02-02 |
| MA34286B1 (fr) | 2013-06-01 |
| US20150231265A1 (en) | 2015-08-20 |
| WO2011140343A1 (en) | 2011-11-10 |
| JP5835717B2 (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012502159A1 (en) | Pharmaceutical compositions and methods of making same | |
| CA2865011C (en) | Methods and compositions for treating huntington's disease | |
| MX2010007471A (es) | Composiciones de nanoparticulas que proporcionan color mejorado para formulaciones cosmeticas. | |
| EP2166991A4 (en) | HYDROGELS BASED ON PVA-PAA | |
| MX340055B (es) | Metodos y composiciones de nanoparticulas sin priones. | |
| MY161495A (en) | Virus like particle compositions and methods of use | |
| MX359639B (es) | Metodos y composiciones para uso en tratamientos celulares. | |
| MX2016001023A (es) | Formulaciones que contienen dapagliflozina amorfa. | |
| MX2013007076A (es) | Articulo absorbente que comprende complejo de ciclodextrina. | |
| WO2010013224A3 (en) | Curcumin nanoparticles and methods of producing the same | |
| WO2011130164A3 (en) | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer | |
| MX375873B (es) | Composiciones de eter sulfoalquilico-ciclodextrina. | |
| WO2009102467A3 (en) | Devices, formulations, and methods for delivery of multiple beneficial agents | |
| GB2528404A (en) | Functionalized environmentally benign nanoparticles | |
| SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| WO2005110438A3 (en) | Methods and products related to the intracellular delivery of polysaccharides | |
| WO2010094009A3 (en) | Methods and compositions for the treatment of ras associated disorders | |
| WO2011148116A3 (fr) | Acide hyaluronique modifie, procede de fabrication et utilisations | |
| WO2008009831A3 (fr) | Derives de cyclodextrines amphiphiles | |
| NZ596876A (en) | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same | |
| WO2012009778A3 (en) | A stable topical composition and a process for producing a stable topical composition | |
| EA201291216A1 (ru) | Бумага для курительного изделия, имеющая свойства, снижающие возможность воспламенения | |
| MX2015009696A (es) | Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph. | |
| HK1223033A1 (zh) | 包括交联的透明质酸和环糊精的组合物 | |
| MX362266B (es) | Composiciones oftalmicas con retención y proteccion de desecación mejoradas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED,, GB Effective date: 20150205 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAY 2016 BY THOMSON REUTERS Effective date: 20150228 |
|
| LAPS | Patent lapsed |